Food ingredients and food improvement agents are increasingly manufactured using biotechnology – from enzymes, flavorings, food colors, to novel foods like human milk oligosaccharides or non-animal protein alternatives. Such innovative products often require a pre-market authorization. The respective application dossiers must include detailed information on the microorganisms used in the manufacturing process. EFSA expects whole genome sequencing data (WGS) on these production strains. To clarify the requirements and expectations, EFSA recently issues a new statement on whole genome sequence analysis of microorganisms intentionally used in the food chain. To read the article in full please click here.
- Advantage for Sponsors to utilize digital subject reporting outcomes (eDiary) in clinical trials
- EFSA’s work on the update or rather reduction of ULs
- Impressions of Probiota 2023: Call for harmonisation and need for clinical trials
- Medical Device Regulation Extension of transition period approved, but what are the implications?
- First Novel food approval for insects in supplements